REGENXBIO Stock Gets Higher EPS Forecast from HC Wainwright

REGENXBIO Inc. (NASDAQ:RGNX) – Investment analysts at HC Wainwright raised their FY2026 EPS estimates for shares of REGENXBIO in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will earn ($3.15) per share for the year, up from their prior forecast of ($3.65). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($3.26) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($1.19) EPS, Q1 2027 earnings at ($1.19) EPS, Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($1.07) EPS, Q4 2027 earnings at ($1.03) EPS and FY2027 earnings at ($4.41) EPS.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.67. The firm had revenue of $9.16 million during the quarter, compared to analysts’ expectations of $10.89 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Saturday. Barclays cut REGENXBIO from an “overweight” rating to a “hold” rating in a report on Friday, August 7th. Robert W. Baird lowered their price target on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating on the stock in a report on Tuesday, August 25th. Morgan Stanley reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Friday, August 7th. Finally, Mizuho set a $18.00 price objective on REGENXBIO in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and an average target price of $23.18.

REGENXBIO Trading Up 5.9%

Shares of RGNX opened at $8.07 on Tuesday. The firm’s 50-day moving average is $7.77 and its two-hundred day moving average is $9.02. REGENXBIO has a twelve month low of $5.45 and a twelve month high of $16.19. The firm has a market capitalization of $532.70 million, a P/E ratio of -2.51 and a beta of 1.24.

Hedge Funds Weigh In On REGENXBIO

Several hedge funds have recently added to or reduced their stakes in RGNX. Versant Capital Management Inc lifted its holdings in shares of REGENXBIO by 60.4% in the second quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 1,032 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of REGENXBIO during the 3rd quarter worth approximately $25,000. Quantbot Technologies LP acquired a new position in shares of REGENXBIO during the 2nd quarter worth approximately $51,000. Legal & General Group Plc acquired a new position in shares of REGENXBIO during the 2nd quarter worth approximately $56,000. Finally, Entropy Technologies LP acquired a new position in shares of REGENXBIO during the 1st quarter worth approximately $87,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.